Bank of Montreal Can raised its holdings in Regenxbio Inc (NASDAQ:RGNX) by 1,906.3% in the second quarter, HoldingsChannel.com reports. The firm owned 37,798 shares of the biotechnology company’s stock after purchasing an additional 35,914 shares during the period. Bank of Montreal Can’s holdings in Regenxbio were worth $2,712,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in the business. Geode Capital Management LLC boosted its holdings in shares of Regenxbio by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 248,328 shares of the biotechnology company’s stock valued at $8,256,000 after purchasing an additional 2,506 shares during the last quarter. Two Sigma Advisers LP acquired a new position in shares of Regenxbio in the 4th quarter valued at $734,000. MetLife Investment Advisors LLC acquired a new position in shares of Regenxbio in the 4th quarter valued at $439,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Regenxbio in the 1st quarter valued at $361,000. Finally, Trexquant Investment LP acquired a new position in shares of Regenxbio in the 1st quarter valued at $233,000. Hedge funds and other institutional investors own 70.60% of the company’s stock.

In related news, Director Donald J. Hayden, Jr. sold 15,000 shares of Regenxbio stock in a transaction on Tuesday, May 15th. The shares were sold at an average price of $50.05, for a total transaction of $750,750.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Vittal Vasista sold 7,500 shares of Regenxbio stock in a transaction on Tuesday, May 15th. The stock was sold at an average price of $50.10, for a total transaction of $375,750.00. The disclosure for this sale can be found here. Insiders have sold a total of 72,600 shares of company stock worth $4,033,675 in the last ninety days. 16.90% of the stock is currently owned by insiders.

A number of equities analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Regenxbio from a “buy” rating to a “sell” rating in a research note on Tuesday, April 17th. BidaskClub raised shares of Regenxbio from a “hold” rating to a “buy” rating in a research note on Friday, April 20th. Barclays reissued an “overweight” rating and issued a $48.00 target price (up previously from $38.00) on shares of Regenxbio in a research note on Wednesday, May 9th. Raymond James set a $45.00 target price on shares of Regenxbio and gave the company a “buy” rating in a research note on Tuesday, May 8th. Finally, ValuEngine raised shares of Regenxbio from a “hold” rating to a “buy” rating in a research note on Friday, May 11th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $64.19.

Regenxbio opened at $67.40 on Friday, MarketBeat reports. Regenxbio Inc has a 12-month low of $19.45 and a 12-month high of $85.10. The firm has a market cap of $2.26 billion, a P/E ratio of -27.51, a PEG ratio of 1.83 and a beta of -1.16.

Regenxbio (NASDAQ:RGNX) last released its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.23 by ($0.93). Regenxbio had a return on equity of 23.27% and a net margin of 37.28%. The firm had revenue of $40.03 million for the quarter, compared to analysts’ expectations of $100.00 million. analysts expect that Regenxbio Inc will post 3.04 earnings per share for the current fiscal year.

Regenxbio Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Read More: Understanding Analyst Ratings

Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regenxbio Inc (NASDAQ:RGNX).

Institutional Ownership by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.